General
Preferred name
TERIPARATIDE
Synonyms
Parathar acetate ()
hPTH 1-34 (acetate salt) ()
Forteo ()
Teriparatide acetate ()
Parathyroid Hormone 1-34, Human ()
Bonsity ()
Forsteo ()
LY333334 ()
Human parathyroid hormone 1-34 ()
LY-333334 ()
1-34-human pth ()
LY 333334 ()
ZT-034 ()
Teriparatide Recombinant Human ()
Pth (1-34) ()
(1-34)-human parathyroid hormone ()
Teriparatide rdna ()
Parathyroid Hormone (1-34) (human) (trifluoroacetate salt) ()
P&D ID
PD071716
CAS
99294-94-7
52232-67-4
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2002
Drug indication
Osteogenesis imperfecta
Bone Resorption Inhibitor
Osteoporosis Therapy Adjunct
Psoriatic disorder
Drug Status
approved
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Teriparatide is a synthetic peptide of amino acids 1-34 of the N-terminal of human parathyroid hormone (). The PubChem and ChEMBL entries linked to above both display a chemical structure for teriparatide. Compare this to the clinical candidate peptide which is a synthetic analogue of human parathyroid hormone-related protein () .
Teriparatide biosimilars and non-originator biologicals are available in countries where patents have already expired. The patents on the reference agent Forteo/Forsteo expire in the US and in Europe in August 2019. The table below lists teriparatide biosimilars that are already approved or are in development.
(GtoPdb)
Teriparatide biosimilars and non-originator biologicals are available in countries where patents have already expired. The patents on the reference agent Forteo/Forsteo expire in the US and in Europe in August 2019. The table below lists teriparatide biosimilars that are already approved or are in development.
| Product name | Company | Clinical phase | Reference |
|---|---|---|---|
| teriparatide similar biologic | Intas Pharmaceuticals | Approved (India 2010) | |
| teriparatide similar biologic | Cadila Healthcare | Approved (India 2012) | |
| teriparatide similar biologic | USV | Approved (India 2012) | |
| Terrosa | Gedeon Richter | Approved (EMA 2017) | |
| Movymia | STADA Arzneimittel AG | Approved (EMA 2017) | |
| Bonsity (PF708) | Pfenex | Approved (FDA 2019) | |
| Sondelbay | Accord Healthcare | Approved (EMA 2022) | |
| Teriparatide Sun | Sun Pharmaceutical Industries | Approved (EMA 2022) | |
| Kauliv | Strides Pharma | Approved (EMA 2023) |
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
12
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Natural product-based probes and drugs
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
4115.13
Hydrogen Bond Acceptors
57
Hydrogen Bond Donors
60
Rotatable Bonds
144
Ring Count
6
Aromatic Ring Count
6
cLogP
-15.24
TPSA
1752.65
Fraction CSP3
0.62
Chiral centers
34.0
Largest ring
6.0
QED
0.01
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PHT
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Osteoporosis
Therapeutic Class
Hormone Therapy
Bone Density Conservation Agents
Source data
